FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula I and their pharmaceutically acceptable salts. The disclosed compounds have inhibitory effect on CDK1 kinase. In formula I 
, R1 is hydrogen or R2-(X)n-; X is a lower alkylene or cyclic lower alkylene; R2 denotes 
; where 
denotes phenyl; cycloalkyl containing 3-6 carbon atoms; 4-6-member heterocycloalkyl ring having 3-5 carbon atoms and 1-2 oxygen atoms; R5, R6 and R7 are independently selected from a group containing hydrogen or halide; R4 is hydrogen or -(O)k(CH2CH2O)y-R10; R19 is hydrogen; R20 is hydrogen or -C(O)-R11; R10 and R11 is a lower alkyl; n and k are equal to 0 or 1; y is an integer from 0 to 3.
EFFECT: obtaining a pharmaceutical composition with inhibitory effect on CDK1 kinase, containing one or more of the disclosed compounds.
15 cl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| QUINAZOLINYLMETHYLENETRIAZOLINONES AS CDK-1 INHIBITORS | 2005 |
|
RU2405782C2 |
| NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | 2005 |
|
RU2391342C2 |
| 4-MONOSUBSTITUTED THIAZOLINE-QUINOLINES | 2005 |
|
RU2397983C2 |
| NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | 2005 |
|
RU2395501C2 |
| 1, 5-NAPHTHYRIDINAZOLIDINONES EXHIBITING CDK1 ANTIPROLIFERATIVE ACTIVITY | 2005 |
|
RU2405781C2 |
| CEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL AGENT | 1994 |
|
RU2130939C1 |
| COMPOUNDS | 2018 |
|
RU2774952C2 |
| PYRAZOLEPYRIMIDINES | 2005 |
|
RU2412186C2 |
| SUBSTITUTED PIRIDAZINE-CARBOXAMIDE COMPOUNDS AS KINASE-INHIBITING COMPOUNDS | 2009 |
|
RU2526618C2 |
| HETEROCYCLIC COMPOUNDS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2015 |
|
RU2667498C2 |
